Synthesis of N-substituted 9-azabicyclo[3.3.1]nonan-3α-yl carbamate analogs as σ2 receptor ligands

Bioorganic and Medicinal Chemistry

Volumn 14, Issue 20, 2006, Pages 6988-6997

  Vangveravong, Suwanna ^a   Xu, Jinbin ^a   Zeng, Chenbo ^a   Mach, Robert H ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

2 Receptors; Fluorescent probe; Two photon microscopy

Indexed keywords

BICYCLO COMPOUND; CARBAMIC ACID DERIVATIVE; FLUORESCENT DYE; N [9 (4 AMINOBUTYL) 9 AZABICYCLO[3.3.1]NONAN 3 ALPHA YL] N' (2 METHOXY 5 METHYLPHENYL)CARBAMATE; N [9 (6 AMINOHEXYL) 9 AZABICYCLO[3.3.1]NONAN 3 ALPHA YL] N' (2 METHOXY 5 METHYLPHENYL)CARBAMATE; RADIOLIGAND; SIGMA RECEPTOR LIGAND; UNCLASSIFIED DRUG;

ARTICLE; BIOTINYLATION; IN VITRO STUDY; LIGAND BINDING; RECEPTOR BINDING; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION; SYNTHESIS;

ANIMALS; AZA COMPOUNDS; BINDING SITES; CARBAMATES; GUINEA PIGS; LIGANDS; MOLECULAR STRUCTURE; RATS; RECEPTORS, SIGMA; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33748102817     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2006.06.028     Document Type: Article

References (21)

1. Martin W.R., Eades C.G., Thompson J.A., Huppler R.E., and Gilbert P.E. J. Pharmacol. Exp. Ther. 197 (1976) 517-532
2. Walker J.M., Bowen W.D., Walker F.O., Matsumoto R.R., de Costa B.R., and Rice K.C. Pharmacol. Rev. 42 (1990) 355-402
3. Hanner M., Moebius F.F., Flandorfer A., Knaus H.-G., Striessnig J., Kempner E., and Glossmann H. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 8072-8077
4. Kekuda R., Prasad P.D., Fei Y.-J., Leibach F.H., and Ganapathy V. Biochem. Biophys. Res. Commun. 229 (1996) 553-558
5. Seth P., Leibach F.H., and Ganapathy V. Biochem. Biophys. Res. Commun. 241 (1997) 535-540
6. Hellewell S.B., Bruce A., Feinstein G., Orringer J., Williams W., and Bowen W.D. Eur. J. Pharmacol., Mol. Pharmacol. Sec. 268 (1994) 9-18
7. Bem W.T., Thomas G.E., Mamone J.Y., Homan S.M., Levy B.K., Johnson F.E., and Coscia C.J. Cancer Res. 55 (1991) 6558-6562
8. Vilner B.J., John C.S., and Bowen W.D. Cancer Res. 55 (1995) 408-413
9. Mach R.H., Smith C.R., al-Nabulsi I., Whirrett B.R., Childers S.R., and Wheeler K.T. Cancer Res. 57 (1997) 156-161
10. Al-Nabulsi I., Mach R.H., Wang L.M., Wallen C.A., Keng P.C., Sten K., Childers S.R., and Wheeler K.T. Br. J. Cancer 81 (1999) 925-933
11. Wheeler K.T., Wang L.M., Wallen C.A., Childers S.R., Cline J.M., Keng P.C., and Mach R.H. Br. J. Cancer 82 (2000) 1223-1232
12. Crawford K.W., and Bowen W.D. Cancer Res. 62 (2002) 313-322
13. Ostenfeld M.S., Fehrenbacher N., Hoyer-Hansen M., Thomsen C., Farkas T., Jaattela M., Nylandsted J., Gyrd-Hansen M., Danielewicz A., Lademann U., Weber E., Multhoff G., Rohde M., Poulsen B., Felbor U., Kallunki T., Boes M., Leist M., Dietrich N., Thastrup J., Holmberg C., Lerdrup M., and Herdegen T. Cancer Res. 65 (2005) 8975-8983
14. Bowen W.D., Bertha C.M., Vilner B.J., and Rice K. Eur. J. Pharmacol. 278 (1995) 257-260
15. Nguyen V.H., Kassiou M., Johnston G.A.R., and Christie M.J. Eur. J. Pharmacol. 311 (1996) 233-240
16. Bonhaus D.W., Loury D.N., Jakeman L.B., To Z., DeSouza A., Eglen R.M., and Wong E.H.J. J. Pharmacol. Exp. Ther. 267 (1993) 961-970
17. Mach R.H., Vangveravong S., Huang Y., Yang B., Blair J.B., and Wu L. Med. Chem. Res. 11 (2003) 380-398
18. Mach R.H., Yang B., Wu L., Kuhner R.J., Whirrett B.R., and West T. Med. Chem. Res. 10 (2001) 339-355
19. Boon J.M., Lambert T.N., Smith B.D., Beatty A.M., Ugrinova V., and Brown S.N. J. Org. Chem. 67 (2002) 2168-2174
20. Cheng Y.C., and Prusoff W.H. Biochem. Pharmacol. 22 (1973) 3099-3108
21. Xu J., Tu Z., Jones L.A., Vangveravong S., Wheeler K.T., and Mach R.H. Eur. J. Pharmacol. 525 (2005) 8-17